The Rise of Radiopharmaceutical Ecosystems
What Belgium’s Radiopharma Valley Can Teach Emerging U.S. Hubs About Attracting Investment, Talent, and Innovation
Radiopharmaceutical site selection is changing how life sciences companies think about location. For years, the questions were familiar. Where is the talent? Where are the research institutions? Where are the incentives? Where can we scale manufacturing?
Today, companies in radiopharmaceuticals face a more complex challenge. The question is no longer simply where a facility can be built. It is which ecosystem can support the entire radiopharmaceutical value chain.
As radiopharmaceuticals transform cancer diagnosis, imaging, and treatment, a small number of regions are becoming globally significant hubs for isotope production, manufacturing, logistics, workforce development, research, and commercialization. Two deserve particular attention:
- Belgium’s Radiopharma Valley
- Indiana’s Radiopharmaceutical Capital of the World® designation and its broader life sciences corridor
They are not alone. Regions across the United States and Europe are competing to attract radiopharmaceutical companies, isotope production facilities, contract development and manufacturing organizations (CDMOs), research operations, and supply chain investments. For site selectors, investors, and corporate decision makers, comparing these ecosystems may become one of the most important competitive analyses in life sciences.
Why Radiopharmaceutical Site Selection Is Different
Radiopharmaceuticals sit at the intersection of nuclear medicine, precision oncology, advanced manufacturing, specialized logistics, research and development, and workforce development.
Unlike traditional pharmaceutical manufacturing, they introduce one unique challenge: time.
Many isotopes begin decaying immediately after production, and some have half-lives measured in hours. As a result, access to isotope production, transportation infrastructure, radiopharmacies, hospitals, and manufacturing assets often matters as much as labor costs or facility availability. That makes this a fundamentally different site selection model.
Belgium’s Radiopharma Valley: The Model Others Are Studying
Belgium has quietly become one of the most important radiopharmaceutical locations in the world. It coordinates approximately 35,000 radiopharmaceutical shipments annually and helps support treatment for roughly 13 million patients worldwide.
Its success comes from an integrated ecosystem that spans the entire supply chain.
Upstream: Isotope Production
Belgium’s BR2 reactor, operated by SCK CEN, is one of the world’s most powerful research reactors. It supplies approximately 25% of global Molybdenum-99 production. Mo-99 is the precursor to Technetium-99m, which is used in approximately 80% of diagnostic nuclear imaging procedures.
Midstream: Processing
The Institut National des Radioéléments (IRE) in Fleurus is one of only a handful of facilities globally capable of processing and purifying critical medical isotopes at scale.
Downstream: Manufacturing
Companies such as Telix Pharmaceuticals and Trasis support radioligand therapies, clean room production, synthesis technologies, and manufacturing infrastructure.
The lesson from Belgium is clear: radiopharmaceutical leadership is built through concentration. Talent, research, isotope production, manufacturing, transportation, and clinical infrastructure all exist within one interconnected ecosystem.
Belgium’s Strengths and Vulnerabilities
Like every leading cluster, Belgium’s success comes with risks.
Strengths:
- Mature nuclear infrastructure
- Deep scientific expertise
- Specialized workforce
- Established isotope production
- Strong public-private coordination
- Integrated supply chain capabilities
Vulnerabilities:
The industry depends on a relatively small number of aging research reactors worldwide, and unexpected maintenance shutdowns can create immediate global isotope shortages. Belgium and the European Union are addressing this through the new European Radioisotope Valley Initiative (ERVI). The initiative seeks to strengthen reactor capacity and reduce dependency on vulnerable supply chains, including materials sourced from Russia.
For companies evaluating international supply chains, geopolitical resilience is now a site selection factor alongside incentives and operating costs.
Indiana: The Radiopharmaceutical Capital of the World®
In July 2025, Indiana secured the trademarked designation Radiopharmaceutical Capital of the World®, reflecting the state’s rapidly growing concentration of radiopharmaceutical assets.
Indiana’s advantages include:
- Fifteen nuclear medicine companies
- The only U.S. supplier of four critical radioisotopes
- Purdue University’s radiopharmaceutical leadership
- Indiana University School of Medicine
- Major industry players including Eli Lilly and Company, Novartis, SpectronRx, and RayzeBio
- Strong logistics infrastructure
The FedEx Global Hub in Indianapolis provides overnight delivery access to much of the U.S. population. That is a significant advantage for products operating under extremely short delivery windows.
Perhaps most importantly, Indiana is building the talent pipeline needed for long-term growth, including Purdue’s dedicated graduate program in radiopharmaceutical manufacturing.
Other U.S. Radiopharmaceutical Hubs to Watch
Indiana is not the only location investing in this sector. Companies evaluating radiopharmaceutical investments should also look at these regions.
Greater Philadelphia, Pennsylvania
Pennsylvania is emerging as a significant Northeast radiopharmaceutical and oncology research hub. It leverages a deep life sciences base, research institutions, and clinical trial capabilities. Organizations such as Nucleus RadioPharma and TerraPower Isotopes are helping strengthen the ecosystem.
Minnesota
Centered around Rochester and Minneapolis, Minnesota benefits from the Mayo Clinic and a growing concentration of CDMO and clinical supply operations supporting radiopharmaceutical development.
Texas
The Texas Medical Center and broader Houston region are increasingly focused on theranostics, clinical production, and rapid logistics, supported by major airport infrastructure and healthcare assets.
Why Whitestown, Indiana Deserves Attention
One of the most interesting emerging locations may be Whitestown, Indiana. It sits approximately twelve miles from Lilly’s LEAP biomanufacturing investment. The Whitestown Life Sciences Campus is being positioned as a future radiopharmaceutical-focused ecosystem connecting:
- Purdue University
- IU Indianapolis
- Indianapolis logistics infrastructure
- Specialized life sciences facilities
- The broader Indianapolis radiopharmaceutical ecosystem
The proposed vision includes radiopharmaceutical production, theranostics, clinical operations, workforce training, and CDMO capabilities. You can see the concept in the Whitestown radiopharma planning materials.
Whether this exact vision evolves or expands, it shows a broader trend: communities are no longer waiting for radiopharmaceutical clusters to emerge organically. They are intentionally planning for them.
5 Site Selection Questions Radiopharma Companies Should Ask
The most successful radiopharmaceutical location decisions increasingly depend on factors beyond incentives. Start by evaluating:
- Workforce capacity: Can the region support specialized manufacturing, quality, engineering, and nuclear medicine roles?
- Logistics infrastructure: Can products reliably reach hospitals, radiopharmacies, and clinical sites before isotopes decay?
- Supply chain resilience: How dependent is the operation on foreign reactors, isotope sources, enrichment facilities, or geopolitical factors?
- Industry concentration: Do suppliers, universities, CDMOs, healthcare systems, and manufacturers already exist within the ecosystem?
- Incentives and public investment: How are state, local, and national incentives aligned with industry growth objectives and long-term expansion?
Companies Are Selecting Ecosystems
The future of radiopharmaceutical site selection may come down to one reality: companies are selecting ecosystems, not just sites.
Belgium’s Radiopharma Valley shows what a mature, integrated radiopharmaceutical cluster can become. Indiana’s Radiopharmaceutical Capital of the World® initiative shows how a U.S. region is intentionally building toward a similar future. At the same time, Pennsylvania, Minnesota, Texas, and other markets are building specialized strengths that deserve close evaluation.
For companies evaluating manufacturing, isotope production, CDMO operations, R&D facilities, or commercialization strategies, the question is no longer “Where can we locate?” It is “Which ecosystem will create the greatest competitive advantage for the next decade?”
That distinction may determine who becomes the next leader in one of the fastest-growing segments of life sciences.
Let’s Talk About Your Next Radiopharmaceutical Project
At Ashmore Consulting, we help companies evaluate competing life sciences markets, analyze workforce and infrastructure readiness, quantify state and local incentives, compare operating costs, and negotiate incentive packages that support long-term corporate objectives.
In radiopharmaceuticals, the strongest location decision is rarely determined by one site or one incentive package. It is determined by the strength of the ecosystem supporting the investment. Contact Ashmore Consulting to start the conversation.
The information contained herein is general in nature and is not intended and should not be construed as legal, accounting, or tax advice or opinion provided by Ashmore Consulting LLC to the reader. The reader is also cautioned that this material may not be applicable to, or suitable for, the reader’s specific circumstances or needs and may require consideration of non-tax and other tax factors if any action is to be contemplated. The reader should contact Ashmore Consulting LLC or another tax professional prior to taking any action based upon this information. Ashmore Consulting LLC assumes no obligation to inform the reader of any changes in tax laws or other factors that could affect the information contained herein.
Ashmore Consulting is proud to join Pledge 1%, a global movement creating new normal where companies of all sizes integrate giving back into their culture and values. Pledge 1% empowers companies to donate 1% of product, 1% of equity, 1% of profit or 1% of employee time to causes of their choice. Over 1,500 companies in 40 countries have taken the Pledge and committed to give to communities around the world. Ashmore Consulting is excited to join Pledge 1%’s network of founders, entrepreneurs and companies around the globe that have committed to giving back.
